alterations have resulted in relatively minor changes in the characteristics of the membrane, for example, cellulose acetate membrane, in which the polysaccharide structure is modified by replacement of hydroxyl ions with acetate radicals. In addition, several synthetic materials have been brought to clinical practice and, in general, are distinguished by a decrease in the intensity and specificity of the blood membrane interactions (Table 1) .
The synthetic polymers can be grouped as either hydrophilic or hydrophobic [4] . In general, the hydrophobic membranes are apolar, have low energy of interactions with water, adsorb proteins, are more porous and have high ultrafiltration coeflicients. This category of hydrophobic membranes includes the polysulfone (PS), the polymethylmethacrylate (PMMA) and the polyacrylonitrile (PAN) membranes [5] . Indeed, the ability of these membranes to adsorb proteins may be a determinant of their biocompatibiity, since membranes such as PAN activate the complement system readily, but have such a high adsorptive capacity for complement activation products that the net effect is only a modest elevation of these products systemically [6] .
Activated pathways
During contact of blood with the hemodialysis membrane, several homeostatic reactions are activated. These include the complement cascade, the coagulation cascade and the interrelated contact-phase reaction. In addition to these proteinmediated pathways, increasing evidence suggests that cellular mechanisms can also be activated during hemodialysis, both upon direct contact of cells with the membrane [7] , as well as byproducts of activation of the humoral pathways, such as complement activation products. Recent work has documented the activation of neutrophils, leading to the up-regulation of adhesion receptors [8, 9] , release of proteinases and other intracellular enzymes, reactive oxygen species [10] , leukotrienes [11] and platelet activating factor (PAF), as well as the activation of monocytes leading to the production of monokines, such as interleukin-1 (IL-i) and tumor necrosis factor (TNF) [12] [13] [14] , and activation of platelets leading to the release of thromboxane B2 [15] [16] [17] . As shown in Figure 1 , in many instances these pathways are interrelated and the participation of one leads to the participation of the other.
The details of activation of these reactions and their enzymatic and non-enzymatic control is beyond the scope of this review. Instead, these reactions will be discussed in terms of their known and potential links to clinical sequelae that have been described in the hemodialysis patient. Hydrophobic synthetic
Acute sequelae of bioincompatibiity Complement activation Although a profound, but transient, neutropenia during hemodialysis was initially observed in 1968, its cause remained unknown until Craddock's elegant work documenting neutropenia and hypoxemia following injection of plasma that had been exposed to cellulosic membrane into rabbits [18, 19] .
Detection of products of complement activation of the common pathway, without evidence of pronounced activation of the classical pathway, have confirmed that complement activation during hemodialysis occurs via the alternative pathway. The extent of complement activation depends on the type of membrane used. In general, cellulose-derived membranes result in a much more profound activation of complement than noncellulosic membranes.
Much research has been devoted to the determinations of surface structures or moieties that govern the activation of complement by biomaterials [20, 21] . The propensity of cellulosic membranes to activate complement is probably related to the polysaccharide structure of cellulose, and specifically to the hydroxyl groups contained in this structure. More recently, the inhibitory role of factor H of the alternative complement pathway has been emphasized. Thus, a membrane that promotes preferential binding of Factor H and does not favor the binding of factor B has a low capacity to activate complement [221. The activation of complement is maximum at 15 minutes but lasts up to at least 90 minutes, following initiation of hemodialysis with new cellulose-derived membranes [23] . As hemodialysis proceeds, the rate of complement activation decreases, as suggested by the difference between the simultaneously drawn efferent and afferent samples across the dialyzer [23] . The mechanisms of passivation of these surfaces after initiation of hemodialysis have not been well defined, but probably include specific deposition of complement fragments such as C3b or Clq, as well as nonspecific deposition of fibrin on the activating sites of the hemodialysis membrane [22] .
Products of complement activation such as C3a and C5a are potent, biologically active agents capable of producing intense vascular smooth muscle contraction, and in several animal models can induce anaphylaxis, hence the term "anaphylatoxin" ( Table 2 ). The spasmogenic effect of the anaphylatoxins on smooth muscle cells is dose-related and the sensitivity of different species to it is variable [24] . Animals exposed to blood in contact with complement activating dialysis membranes developed electrocardiographic changes consistent with ischemia, acute elevations of pulmonary artery pressure and acute reduction of cardiac output, as well as increased vascular permeability and release of histamine from mast cells [25] . Similar acute hemodynamic changes, both in the systemic and pulmonary circulations, are also seen in animals infused with C5a, suggesting that C5a is the putative factor in such reactions [26] .
The clinical relevance of anaphylatoxin release can be ascertained from symptoms that are described in a number of patients during their exposure to a new cellulosic dialyzer. A number of double-blind studies have shown a marked difference in the incidence of adverse symptoms, particularly chest pain, back pain and shortness of breath, between new cellulosic membranes that activate complement vigorously and reprocessed membranes that have a significantly attenuated ability to activate complement [27] [28] [29] [30] [31] [32] . In a prospective study, we also showed that a subset of patients who consistently developed chest pain, back pain and shortness of breath during the first few minutes of bemodialysis, appeared to activate the complement pathway more vigorously (or clear the anaphylatoxin products more slowly). In any case, these patients had levels of C3a and C5a, which were several-fold higher than other patients dialyzed with the same membrane surface [33]. This difference in the level of anaphylatoxins is likely to be the explanation for the "First-Use Syndrome" which affects 5 to 10% of patients receiving hemodialysis with new cellulosic membranes, particularly ones with large surface areas and hence, a greater propensity to activate complement [34] . Whether these anaphylatoxins act directly by themselves or via their action on mast cells and liberation of histamine is not clear at present. It must be stressed that these symptoms, which are directly attributable to the extent of complement activation [35] , are separate from the reactions that have characterized some of the more dramatic reports of anaphylactic-type reactions and which have been found to be due to ethylene oxide antigenicity [36] [37] [38] .
Contact pathway activation
The mechanism by which a surface induces contact pathway activation involves the binding of Hageman factor (Factor XII) and circulating complexes of high molecular weight kininogen (HMWK) with pre-kallikrein. Activation of Hageman factor and pre-kallikrein results in the formation of kallikrein at the surface and is subject to regulation by several plasma inhibitors, such as a2-macroglobulin [39] . This pathway is more easily activated by negatively charged surfaces, because the first step in the activation depends on the charge-induced conformational changes in Factor XII or Hageman factor. This conformational change allows reciprocal activation of kallikrein and Hageman factor. Once activated, kallikrein is also potent in liberating kinins from HMWK as shown in Figure 1 . As expected, the extent of activation of this pathway is generally related to the extent of negative surface charge on a membrane. A recent study has investigated the surface charges of hemodialysis membranes and found that whereas the Cuprophane® membrane has a neutral charge, the polyacrylonitrile (PAN) membrane has a high negative charge ( Lemke and Fink, has shown that in the presence of ACE inhibitors, large amounts of bradykinin are generated in a dose-dependent manner when blood is in contact with the PAN (AN-69) membrane, but not the Cuprophane® membrane [44] . Thus, the variability in the incidence of anaphylactic reactions may reflect different systemic concentrations of the ACE inhibitors and bradykinin levels. More recently, such reactions have been reported in patients on ACE inhibitors and dialyzed with polysulfone and cellulose acetate membranes that have been reused with Renalin® [45] . At present, there are no data on the surface charges of these membranes or whether these reactions are related to the membrane or sterilant-membrane interaction. recent studies of large populations that have documented a higher incidence of amyloid bone disease in patients chronically dialyzed with cellulosic-type membranes. Although some studies showed an increase in the incidence of AJ32m in patients dialyzed with cellulosic membrane, but which were not statistically significant [521, others that were methodologically more rigorous have shown clear-cut statistical significance [53] [54] [55] [56] [57] . The best example is a study by van Ypersele and his group from Belgium, which clearly showed that the "survival without amyloid bone disease" is significantly shorter in patients dialyzed with Cuprophane® membrane than in patients dialyzed with the PAN membrane [53] . The difference in relative risk was clearly higher the older the patient; for example, a 60-year-old patient dialyzed with the Cuprophane® membrane had difference [66, 67] . Although serum /32m levels may not increase appreciably during hemodialysis with cellulosic membranes, particularly if intradialytic changes in extracellular volumes are taken into account, it must be recalled that the additional synthesis induced by the bioincompatibility of the membrane is small compared to the high serum concentration of 132m that results from loss of excretion by the native kidneys in patients with end-stage renal disease [67] [68] [69] .
An additional factor in the propensity of patients dialyzed with cellulosic membranes to develop f32m amyloid bone disease may be due to the fact that most of the cellulosic membranes are "low-flux" membranes; these membranes do not have pore sizes large enough or an adsorptive surface to effect a significant clearance of 132m from the circulation.
Because of these factors, patients dialyzed with biocompatible, high-flux membranes, have a pre-hemodialysis plasma f32m level that is approximately 30% lower than patients dialyzed with the Cuprophane® membrane [70] . Thus, patients on Cuprophane membrane are chronically exposed to a higher level of /.32m. More importantly however, is the fact that the activation of neutrophils by cellulosic membranes leads to the release of proteases, as well as reactive oxygen species, which may further enhance the polymerization of /32m into amyloid fibrils. Indeed, analysis of the amino acid sequence of 132m amyloid fibrils has revealed that these deposits consist of intact f3m fibrils, as well as lysine-specific cleavage fragments of f32m that represent limited proteolysis of /32m by proteases, such as those released by activated neutrophils [71] . In preliminary work, we demonstrated that f.m released by the spontaneous activation of endothelial cells in culture can be identified as a single band (at the 12 KD region) by gel electrophoresis, whereas f32m released during contact with endothelial cells with CSa-activated-neutrophils had multiple bands, representing multimers of the intact f3m molecule [72] . This suggests that a microenvironment of activated neutrophils, endothelial cells and complement fragments, such as exist in the pulmonary vasculature during hemodialysis with cellulosic membranes, may be conducive to the polymerization of f32m [73] . Thus, it is likely that the relationship of hemodialysis with cellulosic membranes to the development of A2m bone disease is due to a combination of increased synthesis, lack of removal, and conditions that favor the polymerization of p2m.
Incidence of infection
Despite many advances in the range of antimicrobial therapy and in the care of patients on chronic maintenance hemodialysis over the past two decades, there has been virtually no change in the incidence of life-threatening infection in hemodialysisdependent patients. Many studies have shown that infections cause approximately 20% of all deaths in this patient population. A more recent study, using careful chart reviews, suggested that infection-related mortality is much higher and accounted for more than 36% of all deaths. Beyond six years of hemodialysis, infections were the most common cause of death in patients starting hemodialysis under the age of 60 years [74] . The majority of these infections are generally due to common catalase-producing bacteria rather than to opportunistic infections.
Although patients on chronic hemodialysis have multiple co-morbid conditions that predispose them to the development of infections (repetitive breaks of skin integrity during cannulation of fistula, malnutrition, etc.), there is increasing evidence that the hemodialysis membrane plays an important role in this enhanced susceptibility to infections.
The repetitive exposure of blood to bioincompatible cellulosic membranes leads to the recurrent activation of complement, degranulation of neutrophils and the release of reactive oxygen species [10, 23] . Although the reactive oxygen species are bactericidal, the unintended release of these molecules during hemodialysis with cellulosic membranes results in detrimental effects consistent with tissue injury [75] , and importantly, in decreased responsiveness to further stimuli [76] ; this refractoriness occurs particularly intradialytically when the skin integrity is violated and the patient is directly exposed to potentially non-sterile surfaces [10, 77, 78] . Chronic hemodialysis with the cellulosic membrane also leads to the attenuation of the ability of neutrophils harvested pre-hemodialysis to respond to phagocytic stimuli [76] .
Almost all studies examining granulocyte chemotaxis, adherence and expression of receptors involved in phagocytosis have demonstrated substantial defects in patients dialyzed with the Cuprophane° membrane, even when compared to uremic patients prior to initiation of hemodialysis [76, 79, 80] . These defects in patients dialyzed with the cellulosic membrane are most prominent intradialytically. A recent study has also demonstrated a significant decrease in the expression of L-selectins on neutrophils harvested during hemodialysis; L-selectins are the receptors known to be involved in granulocyte-endothelial adhesion [81] [82] [83] . Indeed, endothelial cell adhesion has been shown to be significantly decreased when neutrophils are harvested during hemodialysis with the cellulosic membrane, but not when they are harvested from patients dialyzed with the PMMA membrane [81] . This defect may impact on the ability of neutrophils to extravasate through endothelial cells to sites of infection, and may thus play a role in the incidence of infections in hemodialysis patients.
Monocytes, which function as circulating macrophages and play a crucial role in antigen presentation and immune response, are also activated during hemodialysis with cellulosic membranes. Therefore, chronic exposure to these membranes also leads to their refractoriness of monocytes to further stimuli [10, 84, 85] . Several studies have documented defects in monocyte function in hemodialysis patients, such as defective Fcreceptor function [86] and monocyte-dependent IL-2 production by activated T cells [87, 88] . In an in vitro model of hemodialysis, monocyte function was found to be significantly decreased during exposure to cellulosic membranes [85] .
Other studies have also pointed out specific defects in the cellular immunity of patients dialyzed on different membranes [89] [90] [91] [92] . Recent studies from our laboratory have demonstrated that chronic hemodialysis with cellulosic membranes exacerbates the defect in T cell function in hemodialysis patients. By examining the expression of high-affinity IL-2 receptors, which are crucial in the immune response, we found that chronic exposure of patients to these bioincompatible membranes significantly attenuates the expression of high affinity IL-2 receptors on mononuclear cells. The change of dialyzer membrane to a more biocompatible surface, such as PMMA, improves the expression of these receptors and these patients have high affinity IL-2 receptors comparable to those found in normal controls [93] . Raij and Ray found decreased activity of natural killer (NK) cells in blood from normal volunteers exposed to different hemodialysis membranes [94, 95] . Our own studies have confirmed that in patients chronically hemodialyzed with bioincompatible membranes, there was a significant decrease in NK cytolytic activity against their classical target cells K562 [96] . Refractoriness to mitogen stimulation, decreased proliferative response, decreased IL-2 generation and the depressed mixed lymphocyte reactions have also been documented in patients hemodialyzed with the Cuprophane® membrane compared to patients dialyzed with biocompatible membranes [97] [98] [99] .
The association of cellulosic membranes with a higher incidence of clinical infection in chronic hemodialysis patients is supported by retrospective studies which compared the major causes of mortality in approximately 1,000 patients before and after their hemodialysis membranes were changed from a cellulosic to a biocompatible membrane [100] . The most significant difference in the cause of death between these two periods of time was in the incidence of infection, which was decreased by approximately one-half during the period they were dialyzed with the biocompatible polysulfone membrane. These dramatic results were confirmed by another study, in which the rate of hospitalization for infections in patients switched to a PS membrane was half the rate of hospitalization for infections in patients dialyzed with the Cuprophane® membrane [101] . In another study, patients randomized to chronic hemodialysis with cellulosic membranes had a significantly attenuated metabolic response to phagocytic stimuli such as latex or zymosan, compared to neutrophils similarly harvested pre-hemodialysis from patients on the biocompatible polysulfone membrane [76] . Interestingly, during a follow-up of approximately six months, there was also higher incidence of clinical infections in the patients initiating hemodialysis on the Cuprophane® membrane, compared to those initiated on the polysulfone membrane; however, because of the small number of patients, the results had only marginal statistical significance.
Other studies have confirmed an improvement in the lymphopenia in patients on chronic hemodialysis once their hemodialysis membrane was changed to a biocompatible high-flux membrane [97] . Nevertheless, studies to document changes in clinical cellular immunity (such as, specific antibody formation in response to vaccines) as a function of hemodialysis with membranes of different biocompatibilities have not been published [87, 102] .
Resolution of acute renal failure
The suggestion that the dialytic procedure itself may impact on the rate of recovery from acute renal failure (ARF) was first put forward by Solez et al and Conger et al [103, 104] . They examined the histology of renal tissue obtained from wounded soldiers who developed ARF and required hemodialysis for a prolonged period of time. They commented on the presence of fresh areas of tubular necrosis, even though the initial injury was remote. These observations confirmed comments by several clinical nephrologists that the institution of hemodialysis in patients with ARF, who may have modest residual renal function, often causes cessation of urine flow and further loss of residual renal function once hemodialysis is initiated. It was postulated that loss of autoregulation of renal perfusion combined with episodes of hypotension during hemodialysis results in new areas of ischemia in the kidney [105] .
Other investigators have pointed out the adverse role that infiltrating leukocytes can play in the recovery of ARF in several experimental models of obstruction and nephrotoxic serum nephritis [106, 107] . More recently, Linas and his colleagues have shown that the adverse effects of activated neutrophils are particularly evident on an ischemic kidney [108] . Thus, when isolated kidneys were made mildly ischemic and exposed to activated neutrophils, the GFR was considerably reduced. However, this did not occur when the isolated kidneys were exposed to non-activated neutrophils.
Our own previous work using a rat model with reversible ARF showed that the extent of recovery of ARF in animals exposed to stimuli that activated complement and granulocytes, such as the cellulosic hemodialysis membrane, is considerably less and slower than in animals with the same degree of renal failure exposed to a biocompatible (PAN) membrane [109] . The delayed recovery in the group of animals exposed to Cuprophane® was also associated with the presence of increased numbers of activated neutrophils in the renal parenchyma.
Following this lead, a recent abstract outlined the preliminary results of a clinical study in which patients with all forms of ARF requiring hemodialysis were sequentially randomized to dialyze with either Cuprophane® membrane or the biocompatible low-flux PMMA membrane. These results suggest a statistically significant improvement in patient mortality and in the recovery of renal function in patients dialyzed with a biocompatible membrane compared to the group of patients dialyzed with the Cuprophane® membrane. Equally important, in patients who recover, the recovery occurred earlier in the group of patients dialyzed with the biocompatible membrane [110] . If confirmed, the clinical implications of these findings in terms of patient survival and hospitalization costs are quite important.
Catabolic effects of bioincompatibility
Several reports have documented the prevalence of malnutrition, as well as the adverse effects of this malnutrition on morbidity and mortality of the hemodialysis patient [111] . Malnutrition often occurs with protein intakes well above the minimum required for normal controls, suggesting a catabolic process in the hemodialysis-dependent patients. Indeed, patients on hemodialysis appear to have an accelerated catabolic process, which is particularly evident on hemodialysis days.
An important and emerging factor in this catabolic process is the hemodialysis membrane, an area that has been highlighted by several recent studies. Those by Bergstrom, Alvestrand and colleagues in Sweden, clearly point to a net protein catabolism when normal subjects were exposed (not dialyzed) to cellulosic membranes, but not when exposed to the PS or PAN (AN-69) membrane [112, 113] . By measuring net release of specific and total amino acids, they calculated that a 150 minute exposure to the Cuprophane® membrane resulted in a net degradation of approximately 15 to 20 g of muscle protein [112] . It is perhaps worthwhile to point out that in these studies the net release of ammo acids observed was not during the exposure to the membrane, that is, during the first 150 minutes, but was seen approximately six hours after the start of hemodialysis and three hours after the end of hemodialysis. In a few subjects where the observations were continued, the amino acid release continued for up to nine hours after the start of hemodialysis [112] . It is therefore important that studies of the effect of the biocompatibility of hemodialysis membranes on the protein catabolic rate, and the possible effects of monocyte activation and cytokine release, be extended to the time frame in which these cytokines are known to cause an effect. Indeed, these observations are in line with the known time frame of monocyte activation, release of cytokines and their subsequent action on muscle cells [7, 14, 114] .
These experimental studies are also supported by the observations of Lindsay that the relationship between the dose of hemodialysis (Kr/V) and the protein intake (reflected by the protein catabolic rate) was different for different membranes. Patients dialyzed on biocompatible membranes may have a better protein intake than patients dialyzed with a non-biocompatible membrane [115] . These observations are clearly in need of further confirmation by prospective clinical studies, but the evidence so far supports the hypothesis that the biocompatibility of the dialzyer membrane plays a substantial role in the catabolic process associated with hemodialysis, and may be a factor in the prevalence of malnutrition in the hemodialysis patient [111, 113] .
Morbidity and mortality of hemodialysis patients
There are, at present, no randomized studies to judge the effects of biocompatibiity of hemodialysis membrane on the serious morbidity (that is, hospitalization) and mortality of hemodialysis patients. However, two non-randomized studies support the possibility that the use of biocompatible membranes is associated with improvement in morbidity and mortality when compared to patients dialyzed with the cellulosic membrane.
Chanard et al, studied the morbidity of hemodialysis in two groups of patients comparable in age, the major factor determining morbidity and mortality [116] . One group of 31 patients was dialyzed with a Cuprophane® membrane and their morbidity was compared with another group of 31 patients dialyzed with the PAN membrane over approximately 9,000 hemodialysis sessions. The number of hospitalizations was significantly higher for the Cuprophane® group (6.0 1.1 days/patient/year) than for the PAN membrane group (2.1 0.5 days/patient/ year).
A more recent study compared the survival of patients who were switched from hemodialysis with a Cuprophane® membrane to hemodialysis with a high-flux biocompatible (PS) membrane [101] . Of the 80 patients who died during the study period, 69 were receiving conventional hemodialysis with cellulosic membranes and 11 were receiving hemodialysis with the high-flux, biocompatible polysulfone membrane. Multivariate analysis, adjusted for all known comorbid conditions, showed that annual mortality was substantially less for patients treated with the biocompatible high-flux membrane, compared with that for patients treated with conventional hemodialysis (7% vs. 20%, P < 0.001). Although in the study there was no difference in the overall rate of hospital admissions, the infection-related admissions were twice as high for the cellulosic group than for the high-flux, bicompatible membrane group.
Finally, preliminary analysis by Lowene of more than 340 dialysis facilities in the National Medical Care system showed that the average standardized mortality ration (SMR) for facilities using high-flux polysullone membranes was 0.72 compared to patients in dialysis units utilizing cuprophane membrane.
(P < 0.005) [117, 118] .
As discussed earlier, the PS membrane differs from the cellulosic membranes, not only in its biocompatibility but also in terms of its high-flux capability, clearance of middle molecules, and generally larger surface areas that allows for greater reduction of urea per unit of time. The relative importance of any of these factors in the improvement of mortality cannot be clearly ascertained from these studies. While there are only limited data to support the influence of middle molecules on these outcomes [77, 119] , there are data to support an influence of urea reduction on mortality [120] . Indeed, the preliminary analysis by Lowrie indicates that adjustment for urea reduction, using unequilibrated post-dialysis urea levels, attenuates the differences in average SMR. Nevertheless, units that use polysulfone membranes still had a lower average SMR (0.83 compared to units utilizing cellulosic membranes, P = NS) [118] .
In the context of the previous disussion on the consequences of biocompatibility on neutrophil, monocyte and lymphocyte activation, it is likely that the biocompatibiity characteristics of the high-flux membrane play an important role in the differences of mortality shown by these three independent studies.
Potential sequelae of bloincompatibiity
The evidence for the sequelae of bioincompatibility of the hemodialysis membrane in the specific areas discussed above is supportive, but perhaps not conclusive. There are other areas in which membrane bioincompatibility may play a role, but the available evidence is either based primarily on animal data or in vitro work. Nevertheless, it is worthwhile to mention those areas as potential areas for further investigation.
Residual renal function Clinical observations have long confirmed the possibility that initiation of hemodialysis is associated with a rapid decrease in the residual renal function of patients with chronic renal disease; patients who have managed to maintain a low GFR of around 10 mllminute for several months, lose it very quickly once they are started on bemodialysis. The rate of decline of residual renal function is twice as fast in patients starting hemodialysis than in patients starting peritoneal dialysis [121] .
Although there are no prospective clinical trials that have confirmed the possible influence of bloincompatibility or the use of cellulosic membranes on the rate of decline of residual renal function, recent studies on animals with remnant kidneys (5/6 nephrectomies) suggest that such repetitive exposure may play a role. In groups of animals exposed (but not dialyzed) to the Cuprophane® membrane, there is a faster decline of residual renal function than in identical groups exposed to the PAN membrane [122] .
The pathophysiology of these observations in patients and in the animal model has not been elucidated. However, it is likely that they are related to the extent of complement activation by different hemodialysis membranes. Although the activation of complement has been linked predominantly to the generation of anaphylatoxins such as C3a and C5a, recent evidence suggests that the subsequent generation of the terminal membrane attack complex (MAC), C5b-9 may also be a clinically important consequence of complement activation [123, 124] . A number of studies have clearly shown that the MAC is important in the development and propagation of several models of experimental glomerulonephritis [125] . Thus, the chronic activation of complement resulting in the generation of C5b-9 during hemodialysis with cellulosic membranes may well be involved in the more rapid decline of residual renal function in patients initiating hemodialysis. Clinical studies to document these differences in patients initiating hemodialysis with different membranes are ongoing.
Pulmonary changes
The recurrent contact of activated neutrophils and pulmonary endothelium during hemodialysis with cellulosic membranes has been discussed as a potential mechanism that favors the development of f32m amyloid bone disease (see above). A specific protease that is released by activated granulocytes is elastase [126] . Preliminary experiments in our laboratory have confirmed that in patients dialyzed with cellulosic membranes, there is a large increase in the concentration of elastin fragments, most likely from the lung parenchyma. Although these proteases are inactivated by several inhibitory proteins (a2-macroglobulin), there is evidence that the inhibitory proteins function less well in the presence of reactive oxygen species. It is possible, therefore, that patients chronically dialyzed with cellulosic membranes undergo chronic breakdown of their pulmonary elastin fibrils and have a higher propensity for the development of emphysematous changes than patients dialyzed with biocompatible membranes [127] [128] [129] . Such a study, however, has not been done.
Dialysis associated hypoxemia is multifactorial; the major determinant is hypoventilation seen with acetate dialysate and changes in respiratory quotient. However, in well-designed trails, DeBroe [29] and others [130] showed an important contribution from membrane bioincompatibility manifested as leukopenia.
RBC survival
Red blood cells act as major site for deposition of C5b-9, the membrane attack complex. The presence of protein S in plasma and two membrane proteins [homologous restriction factor (HRF) and membrane inhibitor of reaction lysis (MIRL)] act to attenuate the attachment of MAC on cells [131, 1321. However, once C5b-9 is deposited, it leads to the lysis of host cells by insertion of MAC into the membrane and by forming a lesion that results in a lethal or sublethal damage to the cell.
The potential clinical relevance of MAC would be evident in the determination of RBC half-life in patients dialyzed with different membranes. This has not been examined in wellcontrolled studies, but preliminary experiments in our laboratory suggest an increase in RBC osmotic fragility in patients dialyzed with Cuprophane® membrane, in contrast to the same patients dialyzed with a biocompatible membrane. Studies to define the RBC half-life or the sensitivity to similar doses of erythropoietin of patients dialyzed on different membranes have not been performed so far.
Conclusions
The biocompatible hemodialysis membrane can be defined as one that elicits the least amount of inflammatory response in patients exposed to it. These inflammatory responses have clinical consequences that range from acute hemodynamic instability (as in the first use syndrome and the anaphylaxis associated with the use of angiotensin-converting enzyme inhibitors and specific membranes) to the development of 132m amyloid disease. An increased incidence of infections, slower recovery of function after acute renal failure, and improvement of morbidity and mortality may also be related to the biocompatibility characteristics of the hemodialysis membrane. Other potential consequences include the more rapid loss of residual renal function, development of emphysematous pulmonary changes consistent with loss of elastin from the lung and a decrease in RBC half-life. These actual and potential consequences of the hemodialysis membrane suggest that the biocompatibility of the membrane should be an important consideration in the prescription of hemodialysis. 
